Late steroid resistance in childhood nephrotic syndrome: Do we now know more than 40 years ago?

Oleh M. Akchurin, Frederick J. Kaskel

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The formation of steroid resistance in children with nephrotic syndrome (NS) who were initially steroid responsive was described decades ago but has not been studied in sufficient depth. Except for the International Study of Kidney Disease in Children, conducted more than three decades ago, when only cyclophosphamide was available as a second-line agent in steroid-resistant NS, only a handful of small studies have addressed the problem of late steroid resistance (LSR) over the past 40 years. Epidemiology and risk factors for the formation of LSR and differences in outcomes when compared with initial steroid resistance still remain unknown. While multiple second-line treatment choices (calcineurin inhibitors, mycophenolate mofetil, rituximab) exist today, therapeutic approaches to the patients with LSR remain empirical, as no evidence-based data have become available. In the current issue of Pediatric Nephrology, Straatmann et al. report retrospective data on the treatment outcomes for 29 pediatric NS patients with LSR from eight participating centers of the Midwest Pediatric Research Consortium. The authors describe a current pattern of second-line agents used in their cohort and show that the majority of patients (66 %) achieved complete or partial remission after a period of observation for 85 ± 47 months. The authors also describe the data on renal histology. While these data represent an important step forward in our understanding of LSR, further work is needed before firm clinical recommendations can be made. Large-scale prospective studies are required to answer important questions about the epidemiology, genetics and outcomes in late steroid-resistant NS, explore the role of medication adherence and develop evidence-based practice guidelines.

Original languageEnglish (US)
Pages (from-to)1157-1160
Number of pages4
JournalPediatric Nephrology
Volume28
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

Nephrotic Syndrome
Steroids
Pediatrics
Mycophenolic Acid
Nephrology
Medication Adherence
Molecular Epidemiology
Evidence-Based Practice
Kidney Diseases
Practice Guidelines
Cyclophosphamide
Histology
Epidemiology
Observation
Prospective Studies
Kidney

Keywords

  • Focal segmental glomerulosclerosis
  • Immunosuppressant therapy
  • Late steroid resistance
  • Nephrotic syndrome
  • Outcome of nephrotic syndrome

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Late steroid resistance in childhood nephrotic syndrome : Do we now know more than 40 years ago? / Akchurin, Oleh M.; Kaskel, Frederick J.

In: Pediatric Nephrology, Vol. 28, No. 8, 08.2013, p. 1157-1160.

Research output: Contribution to journalArticle

@article{ab7c402f44e74715a31ebdf99777ecfd,
title = "Late steroid resistance in childhood nephrotic syndrome: Do we now know more than 40 years ago?",
abstract = "The formation of steroid resistance in children with nephrotic syndrome (NS) who were initially steroid responsive was described decades ago but has not been studied in sufficient depth. Except for the International Study of Kidney Disease in Children, conducted more than three decades ago, when only cyclophosphamide was available as a second-line agent in steroid-resistant NS, only a handful of small studies have addressed the problem of late steroid resistance (LSR) over the past 40 years. Epidemiology and risk factors for the formation of LSR and differences in outcomes when compared with initial steroid resistance still remain unknown. While multiple second-line treatment choices (calcineurin inhibitors, mycophenolate mofetil, rituximab) exist today, therapeutic approaches to the patients with LSR remain empirical, as no evidence-based data have become available. In the current issue of Pediatric Nephrology, Straatmann et al. report retrospective data on the treatment outcomes for 29 pediatric NS patients with LSR from eight participating centers of the Midwest Pediatric Research Consortium. The authors describe a current pattern of second-line agents used in their cohort and show that the majority of patients (66 {\%}) achieved complete or partial remission after a period of observation for 85 ± 47 months. The authors also describe the data on renal histology. While these data represent an important step forward in our understanding of LSR, further work is needed before firm clinical recommendations can be made. Large-scale prospective studies are required to answer important questions about the epidemiology, genetics and outcomes in late steroid-resistant NS, explore the role of medication adherence and develop evidence-based practice guidelines.",
keywords = "Focal segmental glomerulosclerosis, Immunosuppressant therapy, Late steroid resistance, Nephrotic syndrome, Outcome of nephrotic syndrome",
author = "Akchurin, {Oleh M.} and Kaskel, {Frederick J.}",
year = "2013",
month = "8",
doi = "10.1007/s00467-013-2509-5",
language = "English (US)",
volume = "28",
pages = "1157--1160",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Late steroid resistance in childhood nephrotic syndrome

T2 - Do we now know more than 40 years ago?

AU - Akchurin, Oleh M.

AU - Kaskel, Frederick J.

PY - 2013/8

Y1 - 2013/8

N2 - The formation of steroid resistance in children with nephrotic syndrome (NS) who were initially steroid responsive was described decades ago but has not been studied in sufficient depth. Except for the International Study of Kidney Disease in Children, conducted more than three decades ago, when only cyclophosphamide was available as a second-line agent in steroid-resistant NS, only a handful of small studies have addressed the problem of late steroid resistance (LSR) over the past 40 years. Epidemiology and risk factors for the formation of LSR and differences in outcomes when compared with initial steroid resistance still remain unknown. While multiple second-line treatment choices (calcineurin inhibitors, mycophenolate mofetil, rituximab) exist today, therapeutic approaches to the patients with LSR remain empirical, as no evidence-based data have become available. In the current issue of Pediatric Nephrology, Straatmann et al. report retrospective data on the treatment outcomes for 29 pediatric NS patients with LSR from eight participating centers of the Midwest Pediatric Research Consortium. The authors describe a current pattern of second-line agents used in their cohort and show that the majority of patients (66 %) achieved complete or partial remission after a period of observation for 85 ± 47 months. The authors also describe the data on renal histology. While these data represent an important step forward in our understanding of LSR, further work is needed before firm clinical recommendations can be made. Large-scale prospective studies are required to answer important questions about the epidemiology, genetics and outcomes in late steroid-resistant NS, explore the role of medication adherence and develop evidence-based practice guidelines.

AB - The formation of steroid resistance in children with nephrotic syndrome (NS) who were initially steroid responsive was described decades ago but has not been studied in sufficient depth. Except for the International Study of Kidney Disease in Children, conducted more than three decades ago, when only cyclophosphamide was available as a second-line agent in steroid-resistant NS, only a handful of small studies have addressed the problem of late steroid resistance (LSR) over the past 40 years. Epidemiology and risk factors for the formation of LSR and differences in outcomes when compared with initial steroid resistance still remain unknown. While multiple second-line treatment choices (calcineurin inhibitors, mycophenolate mofetil, rituximab) exist today, therapeutic approaches to the patients with LSR remain empirical, as no evidence-based data have become available. In the current issue of Pediatric Nephrology, Straatmann et al. report retrospective data on the treatment outcomes for 29 pediatric NS patients with LSR from eight participating centers of the Midwest Pediatric Research Consortium. The authors describe a current pattern of second-line agents used in their cohort and show that the majority of patients (66 %) achieved complete or partial remission after a period of observation for 85 ± 47 months. The authors also describe the data on renal histology. While these data represent an important step forward in our understanding of LSR, further work is needed before firm clinical recommendations can be made. Large-scale prospective studies are required to answer important questions about the epidemiology, genetics and outcomes in late steroid-resistant NS, explore the role of medication adherence and develop evidence-based practice guidelines.

KW - Focal segmental glomerulosclerosis

KW - Immunosuppressant therapy

KW - Late steroid resistance

KW - Nephrotic syndrome

KW - Outcome of nephrotic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84879911884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879911884&partnerID=8YFLogxK

U2 - 10.1007/s00467-013-2509-5

DO - 10.1007/s00467-013-2509-5

M3 - Article

C2 - 23708761

AN - SCOPUS:84879911884

VL - 28

SP - 1157

EP - 1160

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 8

ER -